X

Trial Profile

A Phase 1 Open-label Study Of 14c-labeled Talazoparib In Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talazoparib (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Cervical cancer; Ovarian cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Pharmacokinetics
Sponsors Pfizer

Most Recent Events

09 Apr 2019 Results the mass balance, absorption, distribution, metabolism, excretion, and safety of talazoparib published in the Journal of Clinical Pharmacology
23 Aug 2017 Status changed from recruiting to completed.
23 May 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jun 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com